Koninklijke Phil Stock Price, News & Analysis

Royal Philips (NYSE: PHG) announced new innovations in cancer care at the ASTRO annual meeting, including the Multimodality RT Simulation Workspace, which allows for enhanced image fusion and contouring. The company unveiled cutting-edge imaging platforms: MR – Ingenia RT XD and Spectral CT 7500, aimed at optimizing treatment planning. A strengthened partnership with Elekta aims to streamline oncology care, enhancing patient outcomes. With cancer cases expected to rise by 70% in two decades, these innovations address the growing complexity of cancer treatment and improve collaboration among healthcare providers.

Philips reported robust demand with double-digit order intake growth in Q3 2021.

Sales totaled EUR 4.2 billion, reflecting a 7.6% comparable decline due to supply chain challenges and a recall in Sleep & Respiratory Care. Income from continuing operations rose to EUR 442 million.

Order intake surged 47%, while adjusted EBITA was EUR 512 million (12.3% of sales). The company completed its Domestic Appliances divestment, yielding a EUR 2.5 billion gain. Despite supply chain issues, Philips expects low-single-digit sales growth for 2021 and anticipates a return to growth in 2022.

Royal Philips (NYSE: PHG) has launched its next-generation Digital Pathology Suite, aimed at enhancing diagnostic confidence through advanced imaging and AI integration. This scalable solution caters to pathology labs of various sizes, streamlining workflows and improving efficiency. Key features include interoperability with third-party AI tools, superior image quality, and capabilities for team collaboration. The system is designed to alleviate workforce shortages in pathology, thereby aiding personalized oncology care.

Royal Philips (NYSE: PHG) launched the Pediatric Coaching Solution to minimize stress for children undergoing MRI scans. This innovative approach utilizes gamification and a ‘buddy system’ to prepare children, aiming to reduce the use of general anesthesia and enhance patient experiences. The solution includes a mobile app for familiarization with MRI procedures and interactive engagements at the hospital, significantly improving scan quality and potentially lowering healthcare costs. The launch occurs at the International Pediatric Radiology Congress in Rome, with plans for broader applications across different imaging modalities.

On October 4, 2021, Radboud university medical center announced a significant achievement in lung cancer diagnostics using Philips technology. The clinical study reported a 90% diagnostic accuracy in identifying lung cancer through navigation bronchoscopy, leveraging the Philips Lung Suite and Azurion system. Additionally, the average radiation dose per procedure was reduced by over half, from 47.5 Gy·cm2 to 25.4 Gy·cm2. This advancement marks a potential turning point in early lung cancer detection, significant given the high mortality rate associated with the disease.

Royal Philips (NYSE: PHG) has achieved a global consensus from 40 medical experts regarding the use of intravascular ultrasound (IVUS) in peripheral vascular disease (PVD) interventions. The consensus aims to standardize IVUS application to enhance patient care quality. The findings were presented at the Vascular Interventional Advances (VIVA) 2021 symposium. Philips emphasizes the importance of IVUS in delivering tailored treatment plans and improving patient outcomes, underlining its leadership in health technology and commitment to evidence-based guidelines.

Royal Philips (NYSE: PHG) has entered a five-year strategic partnership with Main Line Health to enhance cardiovascular care in Philadelphia. This collaboration aims to integrate advanced cardiovascular solutions, optimizing patient data and workflows, while ensuring cost predictability. The partnership will equip Main Line Health's facilities, including Bryn Mawr and Paoli Hospitals, with state-of-the-art Philips technology, enhancing their ability to deliver high-quality care. Both parties will focus on clinical, operational, and business model innovations to improve patient outcomes and experiences.

Royal Philips has successfully completed the sale of its Domestic Appliances business to Hillhouse Investment for approximately EUR 4.4 billion. The deal includes an enterprise value of EUR 3.7 billion, with cash proceeds after tax of around EUR 3 billion. This transaction will be reported under discontinued operations in Q3 2021. Philips aims to strengthen its remaining Personal Health business, valued at EUR 3.2 billion, focusing on healthy living and disease prevention through innovative solutions. The divestment aligns with Philips' strategy to optimize its health technology portfolio.